Adaptive Biotechnologies Corp Q3 2024 Earnings Revenue Surges to 46. ...
| ADPT Stock | USD 6.46 0.00 0.00% |
Slightly above 60% of Adaptive Biotechnologies' investor base is looking to short. The analysis of overall sentiment of trading Adaptive Biotechnologies Corp stock suggests that many investors are alarmed at this time. Adaptive Biotechnologies' investing sentiment can be driven by a variety of factors including economic data, Adaptive Biotechnologies' earnings reports, geopolitical events, and overall market trends.
Adaptive |
Revenue Achieved 46.4 million for Q3 2024, surpassing analyst estimates of 40.21 million and marking a 22 percent increase year-over-year.Net Loss Reported a net
Read at gurufocus.com
 |
Adaptive Biotechnologies Fundamental Analysis
We analyze Adaptive Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptive Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptive Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Adaptive Biotechnologies is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Adaptive Biotechnologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adaptive Biotechnologies stock to make a market-neutral strategy. Peer analysis of Adaptive Biotechnologies could also be used in its relative valuation, which is a method of valuing Adaptive Biotechnologies by comparing valuation metrics with similar companies.
Peers
Adaptive Biotechnologies Related Equities
| ZURA | Zura Bio | 15.52 | ||||
| IKNA | Ikena Oncology | 1.96 | ||||
| KRYS | Krystal Biotech | 0.99 | ||||
| RPRX | Royalty Pharma | 0.87 | ||||
| ELEV | Elevation Oncology | 0.71 | ||||
| BEAM | Beam Therapeutics | 0.00 | ||||
| LEGN | Legend Biotech | 0.00 | ||||
| HEPA | Hepion Pharmaceuticals | 0.20 | ||||
| VIR | Vir Biotechnology | 0.41 | ||||
| APLS | Apellis Pharmaceuticals | 1.11 | ||||
| VERV | Verve Therapeutics | 2.20 | ||||
| SANA | Sana Biotechnology | 3.43 | ||||
| CRBU | Caribou Biosciences | 5.59 | ||||
| ENVB | Enveric Biosciences | 6.06 |
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.